Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00306969 | Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | 18 | Boston UniversityOTHER | 1 | Mar 27, 2006 | clinicaltrials |
| NCT00035022 | Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas | completed | Phase 1 / Phase 2 | 71 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 13, 2006 | clinicaltrials |
| NCT00234182 | Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC | completed | Phase 1 / Phase 2 | 84 | The University of Hong KongOTHER | 0 | Dec 1, 2005 | clinicaltrials |
| NCT00209625 | Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer | completed | Phase 1 / Phase 2 | 23 | Hokkaido Gastrointestinal Cancer Study GroupOTHER | 1 | Sep 21, 2005 | clinicaltrials |
| NCT00140374 | Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer) | completed | Phase 1 / Phase 2 | 36 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00140387 | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®) | completed | Phase 1 / Phase 2 | 20 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00140400 | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 50 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00116155 | Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | — | Cell GenesysINDUSTRY | 0 | Jun 28, 2005 | clinicaltrials |
| NCT00002136 | A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002137 | A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4 | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002138 | A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days. | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002153 | Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders | completed | Phase 1 | 25 | DEKK-TEC, Inc.INDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002262 | A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma | completed | Phase 1 | — | University of California, San FranciscoOTHER | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002342 | A Study of Tecogalan Sodium | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00027144 | Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase | completed | Phase 1 | 10 | University of ConnecticutOTHER | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00028158 | Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer | completed | Phase 1 / Phase 2 | 65 | MediGeneINDUSTRY | 0 | Jun 24, 2005 | clinicaltrials |
| NCT00028405 | Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors | completed | Phase 1 | 48 | Light Sciences LLCINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00036140 | Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma | completed | Phase 1 | — | PfizerINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00041808 | Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver | completed | Phase 1 / Phase 2 | 20 | FeRxINDUSTRY | 2 | Jun 24, 2005 | clinicaltrials |
| NCT00047762 | Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer | completed | Phase 1 | — | Genentech, Inc.INDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00051675 | Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas | completed | Phase 1 | 30 | XOMA (US) LLCINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00051779 | An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer | completed | Phase 1 | — | Chugai Pharma USAINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Mar 27, 2006source: clinicaltrials